title: Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer.
abstract: Apart from the regulation of calcium metabolism, 1, 25-dihydroxyvitamin D(3) plays an essential role in cell proliferation and differentiation in several tissues. The vitamin D receptor (VDR) gene shows polymorphisms in humans that appear to be clinically significant in some pathological conditions. In the present study, the BsmI polymorphism of the VDR gene was studied in 59 Caucasian patients with rectal cancer (mean follow-up: 48 months). The relationship between VDR genotypes and the expression of oncogenes as well as their influence on survival were also investigated. VDR polymorphism was examined in tumor and normal mucosa cells by PCR technique. The expression of erbB-2/HER-2, p53, ras and epidermal growth factor receptor (EGFR) was also detected by immunohistochemistry and protein blotting. The presence of the VDR B allele significantly correlated with the overexpression of the erbB-2 oncogene. There was no difference in the VDR genotype between cancer and normal mucosal cells. Coexpression of erbB-2, pan-ras, p53 and EGFR internal and external domains was significantly higher in cancer cells than in normal mucosa. There was no significant correlation between VDR genotypes and age, gender, tumor infiltration depth, number and site of lymph node metastases and lymphatic or blood vessel infiltration. The VDR genotype alone did not influence survival. Overexpression of erbB-2 and EGFR was associated with a poor prognosis. In patients expressing only one oncogene in cancer cells, the presence of the VDR B allele showed a tendency to a poor prognosis. In conclusion, VDR gene BsmI polymorphism might affect the development and prognosis of rectal cancer by influencing erbB-2 oncogene expression.
authors.affiliation: First Departments of Medicine, Semmelweis University Medical School, St. John's Hospital Budapest, Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Speer
authors.forename: O
authors.initials: O
authors.lastname: Dworak
authors.forename: K
authors.initials: K
authors.lastname: Cseh
authors.forename: Z
authors.initials: Z
authors.lastname: Bori
authors.forename: D
authors.initials: D
authors.lastname: Salamon
authors.forename: I
authors.initials: I
authors.lastname: Török
authors.forename: G
authors.initials: G
authors.lastname: Winkler
authors.forename: P
authors.initials: P
authors.lastname: Vargha
authors.forename: Z
authors.initials: Z
authors.lastname: Nagy
authors.forename: I
authors.initials: I
authors.lastname: Takács
authors.forename: M
authors.initials: M
authors.lastname: Kucsera
authors.forename: P
authors.initials: P
authors.lastname: Lakatos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017931:DNA Primers; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D012150:Polymorphism, Restriction Fragment Length; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000235:genetics*; D018167:Receptors, Calcitriol / Q000032:analysis / Q000235:genetics*; D012004:Rectal Neoplasms / Q000737:chemistry / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D015854:Up-Regulation; D018631:ras Proteins / Q000032:analysis
chemical_list: D017931:DNA Primers; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D018167:Receptors, Calcitriol; D016159:Tumor Suppressor Protein p53; D018631:ras Proteins